Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report
Immune checkpoint inhibitors (ICIs) have become an important part of malignant tumor therapy. However, some adverse reactions follow ICIs therapy. The incidence of immune-mediated colitis (IMC) has also increased. Here, the case of a 67-year-old male p…